Study of the mechanism of intractable chronic pruriginous skin disease and development new therapeutic drug for these diseases.

2018 Fiscal Year Final Research Report

• Project/Area Number: 16K10168
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Dermatology
• Research Institution: Yokohama City University
• Principal Investigator: Aihara Michiko 横浜市立大学, 医学研究科, 教授 (90231753)
• Co-Investigator(Kenkyū-buntansha): 山口 由衣 横浜市立大学, 医学部, 准教授 (60585264)
• Research Collaborator: HAKUTA amiko ; OKAWA tomoko
• Project Period (FY): 2016-04-01 – 2019-03-31
• Keywords: アトピー性皮膚炎 / かゆみ / コラーゲントリペプチド / セマフォリン / ペリオスチン

Outline of Final Research Achievements

This study aimed to clarify the role of periostin (PO) in atopic dermatitis (AD) and develop a new biomarker and therapy for AD. It was revealed that PO may directly interact not only with keratinocytes but also with fibroblasts and immune cells to exacerbate inflammation in AD. Serum squamous cell carcinoma antigen (SCCA) 2 levels reflected disease severity and clinical type of AD. SCCA2 in combination with PO may thus be a useful biomarker for AD. Collagen tripeptide (CTP), a functional collagen fraction with a high content of Gly-X-Y tripeptides, was investigated for AD treatment. Th2 cytokine productions were inhibited significantly by CTP treatment under AD-like inflammation in human keratinocytes. In the clinical trial, skin inflammation and serum TARC level at week 12 were reduced significantly compared with the initial values in the CTP treated patients. Therefore, CTP may have therapeutic benefit for AD by inhibiting type 2 skewed allergic inflammation.

Free Research Field

薬疹、アトピー性皮膚炎、皮膚アレルギー

Academic Significance and Societal Importance of the Research Achievements

ペリオスチンはサイトカイン産生を介してADの炎症増強に関与することが示されたが、加えて血清SCCA2も難治性ADのバイオマーカーとして有用なことが示されたことから、これらを組み合わせて測定することにより、より精度の高いADのバイオマーカーとなることが期待される。さらにコラーゲントリペプチドのヒト細胞へのTh2抑制効果やAD患者への投与による有効性が示されたことからADの補助治療としてコラーゲントリペプチドの有用性が示唆された。